HOXD13 and lung carcinoma: An increased or stable sPD-1 level independently correlated with longer PFS in two cycles of nivolumab-treated metastatic NSCLC patients, suggesting sPD-1 as a predictive biomarker of response to ICI treatment in patients with lung cancer [51, 52].